RESUMO
OBJECTIVES: To determine: (a) The prevalence of active infection by the hepatitis C virus (HCV) and hepatitis B virus (HBV) in HIV-infected patients, as well as previous exposure to hepatitis A virus (HAV), HBV and HCV. (b) The proportion of patients who have been vaccinated against HAV and/or HBV. (c) The HCV genotype distribution and the percentage of patients who have started treatment against HCV infection. METHODS: All HIV-infected patients who attended the Infectious Diseases Unit of a tertiary care hospital in Southern Spain between September 2008 and February 2009 were included in a prospective cross-sectional study. RESULTS: A total of 520 patients were included. Three hundred and fifty-eight (69%) patients had positive HCV antibody, while 71% of them showed detectable HCV-RNA. The HCV genotype distribution was: 153 (62%) genotype 1, 49 (20%) genotype 3, and 45 (18%) genotype 4. One hundred and thirteen (36.5%) subjects had received treatment against HCV. The prevalence of active HBV infection was 4.4%, while the exposure to HBV was 54.8%. Four hundred and thirty-seven (84%) patients had positive markers of infection of HAV. Of the patients eligible to be vaccinated, 25.6% and 22.3% patients were vaccinated against HAV and HBV, respectively. CONCLUSIONS: The current prevalence of active HCV infection remains high in our area. There were no changes in the HCV genotype distribution. The number of patients with indication for HBV and HAV vaccination and receive these vaccines is low.
Assuntos
Infecções por HIV/epidemiologia , Hepatite B/epidemiologia , Hepatite C/epidemiologia , Adulto , Comorbidade , Estudos Transversais , Feminino , Genótipo , Hepacivirus/genética , Hepacivirus/isolamento & purificação , Hepatite A/sangue , Hepatite A/epidemiologia , Hepatite A/prevenção & controle , Anticorpos Anti-Hepatite A/sangue , Hepatite B/sangue , Hepatite B/prevenção & controle , Anticorpos Anti-Hepatite B/sangue , Hepatite C/sangue , Hepatite C/prevenção & controle , Hepatite C/virologia , Anticorpos Anti-Hepatite C/sangue , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , RNA Viral/sangue , Estudos Soroepidemiológicos , Sexualidade/estatística & dados numéricos , Espanha/epidemiologia , Vacinação/estatística & dados numéricos , Vacinas contra Hepatite ViralRESUMO
Objetivos Determinar en pacientes infectados por VIH: a) La prevalencia de infección activa por el virus de la hepatitis C (VHC) y el virus de la hepatitis B (VHB), así como de la exposición previa al virus de la hepatitis A (VHA), VHB y VHC. b) La proporción que han sido vacunados frente al VHA y/o VHB. c) La distribución genotípica del VHC y el porcentaje de pacientes que han iniciado tratamiento frente al VHC. Métodos Estudio prospectivo de corte transversal. Se incluyeron los pacientes infectados por VIH que acudieron a las consultas de enfermedades infecciosas de un hospital de Andalucía entre septiembre 2008 y febrero 2009.Resultados Se incluyeron 520 pacientes. Trescientos cincuenta y ocho (69%) enfermos presentaban anticuerpos del VHC positivo, mientras el 71% de ellos tenían ARN-VHC detectable. La distribución genotípica del VHC fue: 153 (62%) genotipo 1, 49 (20%) genotipo 3, y 45 (18%) genotipo 4. Ciento trece (36,5%) sujetos habían recibido tratamiento anti-VHC. La prevalencia de infección activa por VHB fue del 4,4%, mientras que la de exposición previa fue del 54,8%. Cuatrocientos treinta y siete (84%) enfermos presentaron anti-VHA positivo. El 25,6 y el 22,3% de los pacientes susceptibles habían sido vacunados frente al VHA y al VHB, respectivamente. Conclusiones La prevalencia actual de infección activa por VHC en los pacientes infectados por VIH sigue siendo elevada en nuestra área. La distribución genotípica del VHC no parece haber sufrido modificaciones notables. El número de pacientes susceptibles de ser vacunados frente al VHA y al VHB que reciben esta terapia preventiva es bajo (AU)
Objectives: To determine: (a) The prevalence of active infection by the hepatitis C virus (HCV) and hepatitis B virus (HBV) in HIV-infected patients, as well as previous exposure to hepatitis A virus (HAV), HBV and HCV. (b) The proportion of patients who have been vaccinated against HAV and/or HBV. (c) The HCV genotype distribution and the percentage of patients who have started treatment against HCV infection. Methods: All HIV-infected patients who attended the Infectious Diseases Unit of a tertiary care hospital in Southern Spain between September 2008 and February 2009 were included in a prospective crosssectional study Results: A total of 520 patients were included. Three hundred and flfty-eight (69%) patients had positive HCV antibody, while 71% of them showed detectable HCV-RNA. The HCV genotype distribution was: 153(62%) genotype 1, 49 (20%) genotype 3, and 45 (18%) genotype 4. One hundred and thirteen (36.5%) subjects had received treatment against HCV. The prevalence of active HBV infection was 4.4%, while the exposure to HBV was 54.8%. Four hundred and thirty-seven (84%) patients had positive markers of infection of HAV. Of the patients eligible to be vaccinated, 25.6% and 22.3% patients were vaccinated against HAV and HBV, respectively. Conclusions: The current prevalence of active HCV infection remains high in our area. There were no changes in the HCV genotype distribution. The number of patients with indication for HBV and HAV vaccination and receive these vaccines is low (AU)